Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 13Terminated 3Recruiting 3Active not recruiting 3Withdrawn 2Unknown 2Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Breast 1

Conditions

Short Bowel Syndrome 1Recurrence 1Rectal Neoplasms 1Colorectal Neoplasms 1Colitis, Ulcerative 1Breast Neoplasms 1

Interventions

Cyclophosphamide 390Carboplatin 344Gemcitabine 332pembrolizumab 329Cisplatin 328Paclitaxel 297Radiotherapy 296Docetaxel 286Bevacizumab 253Rituximab 234Capecitabine 223Nivolumab 220Dexamethasone 206Fluorouracil 190fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 133Cetuximab 129Bortezomib 129fludarabine phosphate 128Lenalidomide 126Erlotinib Hydrochloride 120Filgrastim 119Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Loperamide × Clear all
NCT06865677 2026-01-21

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
2 enrolled 7 charts

Recurrence

NCT04172597 2024-03-13

A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies

Spectrum Pharmaceuticals, Inc

Phase 2 Terminated
1 enrolled 2 charts
BreastGastrointestinal

Breast Neoplasms, Colorectal Neoplasms

NCT02266849 2016-10-11

Loperamide vs. Placebo's Effect on Ileostomy Output: A Clinical Randomized Blinded Cross-over Study

Odense University Hospital

Phase 3 Terminated
12 enrolled
Gastrointestinal

Colitis, Ulcerative, Rectal Neoplasms, Short Bowel Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡